Skip to content

US · MCRB · BIOTECHNOLOGY

Seres Therapeutics, Inc. (MCRB) intrinsic value and stock valuation

$1.24as of 2026-11-21 · Mkt cap 48.47M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Seres Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values MCRB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MCRB’s statements →

Seres Therapeutics, Inc. Graham Number

Graham Number: $8.50d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02140 serestherapeutics.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$790K-52.7% 5y CAGRd
20122025
Net income
$5.7M
20122025
Free cash flow
$860K
20122025
Total equity
$44.2M-24% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$790K$0.00$0.00$0.00$144.9M
Operating income-$-93.97M-$-121.31M-$-195.1M-$-179.91M-$-64.49M
Net income$5.7M-$-146.57M-$-113.72M-$-250.16M-$-65.58M
EPSd$642.6K-$-18.86M-$-17.77M-$-46.33M-$-14.29M
Operating cash flow$1.12M-$-148.61M-$-117.35M-$-228.82M$6.69M
Capital expenditure-$-250K-$-380K-$-7.97M-$-9.82M-$-9.57M
Free cash flow$860K-$-148.99M-$-125.33M-$-238.64M-$-2.88M
Total assets$138.2M$139.8M$358.6M$348.8M$354.9M
Total debt$83M$91.6M$198.8M$162.6M$49.2M
Net debt$37.2M$60.9M$70.8M-$-440K-$-130.79M
Total equity$44.2M$13.8M-$-44.86M$10.8M$131.5M
Cash and short-term investments$45.8M$30.8M$128M$181.3M$290.7M
Income statement
20252024202320222021
Revenue$790K$0.00$0.00$0.00$144.9M
Cost of revenue$4.13M$3.53M$19.3M$0.00$0.00
Gross profit-$-3.34M-$-3.53M-$-19.34M$0.00$144.9M
Research and development expenses$49.1M$64.6M$117.6M$109.7M$141.9M
Selling, general and administrative expenses$39.2M$53.2M$77.5M$70.3M$69.3M
Other expenses$2.41M$0.00-$-19.34M$0.00-$-1.73M
Operating expenses$90.6M$117.8M$175.8M$179.9M$209.4M
Cost and expenses$94.8M$121.3M$195.1M$179.9M$209.4M
Interest income$2.23M$3.97M$7.3M$3.06M$2.87M
Interest expense$0.00$0.00$13.2M$6.02M$2.91M
Depreciation and amortization$4.13M$5.47M$6.24M$6.63M$5.95M
Ebitda$9.83M-$-120.3M-$-181.42M-$-170.93M-$-56.72M
Operating income-$-93.97M-$-121.31M-$-195.1M-$-179.91M-$-64.49M
Total other income/expenses, net$99.7M-$-4.46M$4.97M-$-3.67M-$-1.08M
Income before tax$5.7M-$-125.77M-$-190.13M-$-183.58M-$-65.58M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$5.7M-$-146.57M-$-113.72M-$-250.16M-$-65.58M
Weighted average shares outstanding$8.86M$7.77M$6.4M$5.4M$4.59M
Weighted average diluted shares outstanding$8.87M$7.77M$6.4M$5.4M$4.59M
Balance sheet
20252024202320222021
Cash and short-term investments$45.8M$30.8M$128M$181.3M$290.7M
Net receivables$360K$4.75M$0.00$0.00$0.00
Inventory$0.00$0.00$29.7M$0.00$0.00
Total current assets$49.4M$38.7M$175.4M$194.8M$303.6M
Property, plant and equipment, net$80.1M$92.4M$108M$134M$36.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$8.67M$8.67M$9.59M$9.59M$490K
Total non-current assets$88.8M$101.1M$183.2M$154M$51.2M
Total assets$138.2M$139.8M$358.6M$348.8M$354.9M
Accounts payable$1.68M$4.08M$3.64M$17.4M$13.7M
Short-term debt$10.4M$8.67M$5.59M$4.06M$6.61M
Deferred revenue$0.00$0.00$7.73M$4.26M$16.8M
Total current liabilities$19.3M$41.2M$98.7M$85.6M$82.3M
Long-term debt$72.6M$83M$193.2M$158.5M$42.6M
Deferred revenue, non-current$0.00$0.00$95.4M$92.4M$87M
Total non-current liabilities$74.7M$84.8M$304.8M$252.4M$141.1M
Capital lease obligations$72.6M$91.6M$97.2M$111.5M$24.6M
Total liabilities$94M$126M$403.5M$338M$223.4M
Common stock$10K$170K$140K$120K$90K
Retained earnings-$-972.4M-$-978.1M-$-978.24M-$-864.51M-$-614.35M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-10K-$-60K
Total equity$44.2M$13.8M-$-44.86M$10.8M$131.5M
Total investments$8.67M$8.67M$9.59M$27.9M$111.2M
Total debt$83M$91.6M$198.8M$162.6M$49.2M
Net debt$37.2M$60.9M$70.8M-$-440K-$-130.79M
Cash flow statement
20252024202320222021
Net income$5.7M$140K-$-113.72M-$-250.16M-$-65.58M
Depreciation and amortization$4.13M$5.47M$6.24M$6.63M$5.95M
Stock-based compensation$10.8M$21M$34.1M$25.5M$20.2M
Change in working capital-$-27.78M-$-65.51M-$-58.98M-$-18.39M$41.5M
Accounts receivable$1.55M-$-2.07M-$-8.67M$0.00$9.39M
Inventory$0.00-$-33.8M-$-29.65M$0.00$0.00
Accounts payable-$-2.4M-$-2.94M-$-11.58M$2.2M$9.36M
Net cash provided by operating activities$1.12M-$-148.61M-$-117.35M-$-228.82M$6.69M
Investments in property, plant and equipment-$-250K-$-380K-$-7.97M-$-9.82M-$-9.57M
Acquisitions, net$210K$0.00$0.00-$-92.25M$0.00
Net cash used for investing activities-$-40K$142.3M$10.6M$82.4M$64.1M
Common stock issued$13.9M$23.5M$18.2M$101.2M$2.13M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$13.9M-$-90.37M$71.7M$129.6M$1.18M
Net change in cash$15M-$-96.69M-$-35.06M-$-16.79M$72M
Cash at end of period$54.4M$39.5M$136.2M$171.2M$188M
Operating cash flow$1.12M-$-148.61M-$-117.35M-$-228.82M$6.69M
Capital expenditure-$-250K-$-380K-$-7.97M-$-9.82M-$-9.57M
Free cash flow$860K-$-148.99M-$-125.33M-$-238.64M-$-2.88M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Seres Therapeutics, Inc.

        Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.

        CEO
        Richard N. Kender
        Employees
        66
        Beta
        0.21

        Explore

        Frequently asked questions

        What is the intrinsic value of Seres Therapeutics, Inc. (MCRB)?

        InvestorsCraft does not currently publish an intrinsic value for MCRB. How the IC value is calculated.

        Is MCRB undervalued?

        InvestorsCraft does not publish an undervaluation signal for MCRB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.